Design, synthesis, and biological evaluation of novel napabucasin-melatonin hybrids as potent STAT3 inhibitors.

[1]  Wan-Ting Chen,et al.  Cucurbitacin I inhibits the proliferation of pancreatic cancer through the JAK2/STAT3 signalling pathway in vivo and in vitro , 2022, Journal of Cancer.

[2]  Jinyun Dong,et al.  Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation. , 2021, Journal of medicinal chemistry.

[3]  N. Neamati,et al.  Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91. , 2021, Journal of medicinal chemistry.

[4]  Dingding Gao,et al.  Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy. , 2020, European journal of medicinal chemistry.

[5]  Xiaoning Zeng,et al.  Melatonin modulates airway smooth muscle cell phenotype by targeting the STAT3/Akt/GSK-3β pathway in experimental asthma , 2019, Cell and Tissue Research.

[6]  Zhi-dan Zhang,et al.  Pseudolaric acid B exhibits anti-cancer activity on human hepatocellular carcinoma through inhibition of multiple carcinogenic signaling pathways. , 2019, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[7]  H. Qiao,et al.  Correction to: Suppressive effects of plumbagin on invasion and migration of breast cancer cells via the inhibition of STAT3 signaling and down-regulation of inflammatory cytokine expressions , 2019, Bone Research.

[8]  Li Yan,et al.  STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review , 2019, Journal of Experimental & Clinical Cancer Research.

[9]  A. Tong,et al.  A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3). , 2019, European journal of medicinal chemistry.

[10]  Jian-Ting Zhang,et al.  Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we? , 2018, Pharmacology & therapeutics.

[11]  G. Sethi,et al.  The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies , 2018, Cancers.

[12]  K. Müller,et al.  Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells. , 2018, Journal of natural products.

[13]  Qifan Zhou,et al.  Design, synthesis and activity of BBI608 derivatives targeting on stem cells. , 2018, European journal of medicinal chemistry.

[14]  Yong-Hua Yang,et al.  Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain , 2017, Scientific Reports.

[15]  A. Grothey,et al.  Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor , 2017, Drugs.

[16]  D. Rognan,et al.  Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors. , 2015, European journal of medicinal chemistry.

[17]  H. A. Rogoff,et al.  Suppression of cancer relapse and metastasis by inhibiting cancer stemness , 2015, Proceedings of the National Academy of Sciences.

[18]  Hua Yu,et al.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.

[19]  Q. Shen,et al.  Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention , 2014, Cancers.

[20]  T. Ashizawa,et al.  Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma. , 2013, International journal of oncology.

[21]  Jiayuh Lin,et al.  Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design. , 2013, Journal of medicinal chemistry.

[22]  Shiqiang Yu,et al.  New Role of JAK2/STAT3 Signaling in Endothelial Cell Oxidative Stress Injury and Protective Effect of Melatonin , 2013, PloS one.

[23]  P. Yue,et al.  Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts , 2012, Proceedings of the National Academy of Sciences.

[24]  S. Fletcher,et al.  Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. , 2009, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[25]  W. Guida,et al.  Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity , 2007, Proceedings of the National Academy of Sciences.

[26]  Bianca Sperl,et al.  Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. , 2006, Chemistry & biology.

[27]  Renxiao Wang,et al.  A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Berg,et al.  A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3. , 2004, Analytical biochemistry.

[29]  J. Darnell.  Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.

[30]  D. Blask,et al.  Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. , 2002, Current topics in medicinal chemistry.

[31]  R. Reiter.  Oxidative damage in the central nervous system: protection by melatonin , 1998, Progress in Neurobiology.

[32]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[33]  R. Reiter,et al.  The melatonin rhythm: both a clock and a calendar , 1993, Experientia.

[34]  D. Kingston,et al.  Plant anticancer agents. XII. Isolation and structure elucidation of new cytotoxic quinones from Tabebuia cassinoides. , 1982, Journal of natural products.

[35]  Li Lin,et al.  A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. , 2010, Neoplasia.